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A total of 17 antibodies, raised in several nonhuman species and specific for different regions on the delta
antigen (dAg), were used to map, via immunoprecipitation, those domains exposed on the surface of the viral
ribonucleoprotein (RNP). These studies showed that the domains for the nuclear localization signal and the
C-terminal extension, unique to the large form of dAg, are exposed. Also exposed is the C-terminal region of
the small form of dAg. In contrast, reactivity was not found with the coiled-coil domain needed for protein
dimerization. When the hepatitis delta virus (HDV) RNA was released by treatment of viral RNP with vanadyl
ribonucleoside complexes, no change in the pattern of dAg epitope presentation was detected, consistent with
the interpretation that a multimeric protein structure persists in the absence of RNA. These RNP studies have
implications not only for understanding of the process of HDV assembly but also for evaluation of the immune
responses of an infected host to HDV replication.
During the replication of hepatitis delta virus (HDV), the
major proteins produced are the small and large forms of the
delta antigen (dAg). These dAgs are 195 and 214 amino acids
(aa) long and differ in that the large form has an additional 19
aa at its C terminus (11). In vitro experiments have shown that
a shared property of both forms of the dAg is the ability to bind
RNA, with a specificity for the rod-like folding of the HDV
genome and antigenome (5, 15). Consistent with this binding is
the ability to isolate, by a variety of procedures, ribonucleo-
protein (RNP) complexes from virions (vRNP) and from the
nuclei of infected cells (nRNP) (21). There are two major
structural differences between the vRNP and the nRNP. First,
the vRNP contains predominantly genomic RNA while the
nRNP contains both genomic and antigenomic RNAs. Second,
the relative amount of dAg per molecule of HDV RNA is
higher for vRNP than for nRNP, upon the basis of equilibrium
density sedimentation (21). The aim of the present study was to
use a panel of antibodies which recognize epitopes spanning
the dAg and determine which regions are exposed on the two
forms of RNP and whether or not there are additional struc-
tural differences that can be detected. These findings, particu-
larly in terms of the exposed epitopes, have relevance for the
understanding of both the steps of HDV assembly and the
immune responses of an infected host to HDV replication.
MATERIALS AND METHODS
Plasmids. Construction of plasmid pSVL(D3), containing a replication-com-
petent trimer of HDV cDNA, was reported previously (8). Plasmid pSV45H,
carrying the pre-S1-pre-S2-S gene of hepatitis B virus under the control of the
simian virus 40 early promoter, was kindly provided by Don Ganem (9).
Viruses. HDV was obtained from an experimentally infected woodchuck. The
animal’s serum, containing about 1.2 3 1011 virions per ml, was clarified by
low-speed centrifugation, followed by pelleting of the virus through a 20%
sucrose cushion (Beckman SW27 rotor, 23,000 rpm for 16 h at 48C). The virus-
containing pellet was resuspended in STE buffer (100 mM NaCl, 10 mM Tris-
HCl [pH 8.0], 1 mM EDTA), and the virus was pelleted through another 20%
sucrose cushion (SW60 rotor, 42,000 rpm for 6 h at 48C) and resuspended in STE
buffer.
Virus-like particles. Preparation of particles secreted by HDV cDNA-trans-
fected Huh7 cells (16) was done essentially as previously described (20), with one
alteration: plasmid pSV45H, for expression of all three hepatitis B surface
antigen (HBsAg) proteins, was used for cotransfection with HDV cDNA.
Virion RNP. Virions from two sources were used for the preparation of vRNP:
either those purified from the serum of infected woodchucks or those secreted by
transfected cells. Such virions were disrupted in STE buffer containing 0.5%
Nonidet P-40, 10 mM dithiothreitol (DTT), and 1 U of RNasin (Promega) per
ml for 15 min at room temperature.
Antibodies. An antibody (rab a-dAg) reactive to both the small and large
forms of dAg was raised in a rabbit by inoculation of the small form of dAg
prepared in Escherichia coli. Production of guinea pig antipeptide sera, rabbit
antipeptide sera, and mouse monoclonal antibodies (MAbs) to recombinant dAg
was done as previously described (7, 19, 23). MAbs reactive to hepatitis B core
antigen (HBcAg) (10C6) and HBsAg (S14) were also described previously (3).
S14 was shown to efficiently recognize the nondenatured woodchuck hepatitis
virus surface proteins (unpublished observation). MAbs 3.92, 5.60, and 7.79 were
produced by using standard procedures and synthetic peptide 12-60(Y), synthe-
sized as previously reported (19).
PEPSCAN analyses. Mapping of the epitopes recognized by MAbs and anti-
peptide antibodies to dAg was carried out as previously described (24), by using
a set of 209 plastic pins on which were synthesized nested hexapeptides over-
lapping each other by five residues and spanning the entire large dAg protein
(residues 1 to 214). Rabbit and guinea pig antisera were tested at a dilution of
1:1,000. Murine MAbs (hybridoma supernatant fluids) were tested at a dilution
of 1:250. Pins were considered reactive if they generated an absorbance value
(optical density at 405 nm) of greater than 0.7 with guinea pig antisera, 0.45 with
rabbit antisera, or 0.2 with murine MAbs. These cutoff values were established
from the absorbance obtained with pins bearing peptides outside of the range of
the peptide or dAg expression product used to raise antisera.
Immunoprecipitation. M-280 superparamagnetic beads conjugated with
streptavidin (Dynal) were loaded with biotin-labeled protein A and then with
rabbit or guinea pig antibodies to different epitopes of dAg, as recommended by
the manufacturer. Mouse MAbs were bound to the protein A-loaded beads by
using rabbit anti-mouse immunoglobulin G (Fc fragment) polyclonal antibodies
(Sigma). Beads with antibodies were incubated with vRNP in STE buffer con-
taining 0.5% Nonidet P-40, 10 mM DTT, and 1 U of RNasin per ml for 2 h at
room temperature with rocking. After magnetic separation, the beads were
washed five times with STE buffer and then the beads and supernatant were
immediately subjected to Northern (RNA) blot and immunoblot analyses.
Northern blot analysis. After immunoprecipitation, HDV RNA was extracted
from the beads and supernatant by using a sodium dodecyl sulfate-pronase
procedure (17). After glyoxalation, the RNA was subjected to electrophoresis in
1.5% agarose gels, followed by RNA blotting to detect genomic HDV RNA
sequences. A genomic full-length HDV RNA probe was synthesized in vitro in
the presence of [a-32P]UTP and used as previously described (6). Quantitation
was achieved by using a Fuji Bio-Imaging system (Fujix BAS1000).
Immunoblot analysis. After immunoprecipitation, both the beads and super-
natant were subjected to electrophoresis in 12% polyacrylamide gels by the
method of Laemmli (10). After electrotransfer of proteins to a nitrocellulose
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filter, dAgs were detected with rab a-dAg antibodies and 125I-labeled protein A
(Du Pont). Quantitation was achieved with a Fuji Bio-Imaging system (Fujix
BAS1000).
Immunofluorescence. Monolayer cultures of Huh7 cells on glass coverslips
were transfected with HDV cDNA [pSVL(D3)]. After 6 days, the cells were fixed
and stained as previously described (2). Cells were stained by using mouse
anti-dAg MAbs, guinea pig antipeptide sera, and rabbit antipeptide sera and
corresponding species-specific polyclonal goat anti-immunoglobulin G antibod-
ies conjugated with rhodamine (Sigma). After being mounted, the samples were
viewed with a Zeiss Axiophot microscope with a 403 objective and specific filter
blocks.
RESULTS
RNP preparation. The following experiments were under-
taken to monitor the extent of virus disruption by nonionic
detergent and DTT and the ability to recover the released
RNP free of associated or contaminating complexes of surface
proteins. Virus-like particles secreted by Huh7 cells cotrans-
fected with HDV cDNA [pSVL(D3)] and an HBsAg expres-
sion plasmid were collected and partially purified by sedimen-
tation through a 20% sucrose cushion. After disruption with
0.5% Nonidet P-40 and 10 mM DTT for 15 min at room
temperature, RNP was sedimented through a 20% sucrose
cushion. As shown in Fig. 1, the undisrupted particles (lane 1)
and the RNP pellet fraction (lane 2) were assayed by immu-
noblotting to detect HBsAg (Fig. 1A) and Northern analysis to
detect HDV genomic RNA (Fig. 1B). Quantitation of these
data showed that ,2% of the HBsAg was in the pellet fraction
while 96% of the HDV RNA was recovered. Our interpreta-
tion is that disruption with Nonidet P-40 and DTT released
RNP from associated HBsAg. The same fraction (95%) of
HDV RNA was found in RNP after disruption of serum-
derived HDV virions under the same conditions.
Immunoprecipitation of vRNP. We next measured the abil-
ity of the vRNP to be immunoprecipitated by using 17 anti-
bodies recognizing different epitopes of dAg. The ability of the
vRNP to be precipitated was assayed via its two components:
HDV genomic RNA and dAg. This quantitation, along with
some of the characteristics of the antibodies used, are summa-
rized in Table 1. The four functional regions that have previ-
ously been defined for dAg are represented in Fig. 2A, and in
parallel with these are definitions of the specificities of the 17
antibodies used (Fig. 2B). As can be seen from Table 1 and as
represented in Fig. 2B by the shaded boxes, we found that 9 of
the 17 antibodies tested were able to efficiently precipitate the
vRNP under our experimental conditions. For five of these
nine antibodies, only partial shading is presented to reflect the
fact that we were able by PEPSCAN procedures to obtain a
more precise delineation of the epitopes recognized (Fig. 3).
Such detailed epitope mapping was not obtained for the eight
antibodies, shown by open boxes, that failed to immunopre-
cipitate the vRNP.
In previous studies, it was shown that vanadyl ribonucleoside
complexes (VRC) were able to disrupt HDV RNA and dAg in
the vRNP (21). Thus, we examined whether the spectrum of
epitopes exposed on the vRNP would be changed as a result of
VRC treatment. As expected, the results summarized in Table
1 show that the RNA was no longer precipitable by any of the
antibodies tested. However, to our surprise, we found that the
ability to immunoprecipitate dAg was essentially the same as
for the untreated vRNP. In other words, with the antibodies
used we were not able to reveal dAg epitopes that were af-
fected by removal of RNA from the vRNP.
As a control for the ability of nonionic detergent plus DTT
to disrupt HDV and release the vRNP, we made use of an
anti-HBsAg antibody. This antibody was able to precipitate
both RNA and dAg before, but not after, disruption of HDV
virions (Table 1, antibodies 18 and 19). (The observed rela-
tively low efficiency of virion precipitation by the anti-HBsAg
antibody was not due to lack of specificity of the antibody. It
was probably due to the presence in our HDV preparation of
a large excess of empty surface particles, which compete for the
antibody in this assay.) For a negative control, we tested the
unrelated antibody 10C6 to HBcAg; this gave a background
level of 4% for vRNP immunoprecipitation (Table 1, antibody
20). Finally, as a positive control, we used a rabbit polyclonal
antibody raised against the entire dAg; as expected, this gave
efficient immunoprecipitation (Table 1, antibody 21).
Antibody specificity. The inability of certain antipeptide sera
to immunoprecipitate RNP can have multiple causes. One
cause is that the relevant domain is not exposed on the RNP
structure. Another cause could be a critical amino acid se-
quence variation between the peptide used for immunization
and the corresponding antigen found in virions. To exclude this
second possibility, we used alternative assay procedures to
characterize such antibodies. As summarized in Table 1, we
confirmed the ability of the antibodies to recognize dAg in an
enzyme-linked immunosorbent assay (ELISA), immunoblot-
ting, and immunofluorescence microscopy with Huh7 cells
transfected with replicating HDV cDNA (see Materials and
Methods).
DISCUSSION
The aim of these studies was to use multiple antibodies with
known specificity for regions on the dAg to determine which of
these epitopes are exposed on the surface of the HDV RNP.
Several controls were used to verify the complete disruption of
virions with nonionic detergent plus DTT and the quantitative
release and subsequent recovery of the vRNP (Fig. 1 and Table
1); it was shown that after disruption, surface proteins were no
longer associated with RNP, so they could not mask any of the
dAg epitopes and thereby affect the results of our immunopre-
cipitation studies. The results of immunoprecipitation studies
with 17 different antibodies are summarized in Table 1 and Fig.
2B. (i) Results obtained with antibodies 7 and 8 revealed that
the so-called core sequence of the bipartite nuclear localiza-
tion signal is exposed; this indirectly supports the speculation
that in the initial stages of infection, following uncoating, the
viral RNA is delivered to the nucleus as an RNP. (ii) Results
FIG. 1. Disruption of HDV. As discussed in the text, particles were assayed
by immunoblotting for human hepatitis B virus surface proteins (A) and by
Northern analysis (B) for HDV genomic RNA both before (lane 1) and after
(lane 2) disruption and RNP isolation. Viral proteins and RNA are indicated at
the left. sAg-L, large surface antigen; sAg-S, small surface antigen.
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obtained with antibody 17 indicated that the C-terminal exten-
sion unique to the large dAg is exposed; this is consistent with
the essential role of this region in virus assembly, presumably
by promotion of an interaction with the envelope proteins of
the helper virus (4, 20). (iii) Four of five antibodies, 12 to 15,
specific for the C-terminal region of the small dAg were also
reactive; it has been speculated that this region is an assembly
domain (13); however, more recent studies argue that the
19-aa C-terminal extension on the large dAg is both necessary
and sufficient for assembly into particles of individual protein
molecules (14). Our studies reopen the possibility that for
RNP, this region is exposed and thus might have a role in some
process, such as assembly, which involves not just individual
proteins but RNP. (iv) Antibody 9 interacted with the region
adjacent to one side of the bipartite RNA-binding domain
(15). Antibody 10 was also found to be reactive, but lack of
epitope mapping data makes this result less informative. The
antibody failed to react with any of the synthetic peptides
utilized in the PEPSCAN or peptide ELISA; thus, it remains
unclear whether the corresponding epitope resides with the
RNA-binding domain or is adjacent to it, as with the epitope
for antibody 9. Antibody 11 failed to bind to the RNA-binding
domain. Taken together, these studies are not sufficient to
conclude whether or not the RNA-binding domain is exposed.
(v) Finally, six antibodies directed against the coiled-coil do-
main, which is necessary and sufficient for dimerization and
oligomerization (12, 25, 26), failed to recognize the RNP; these
results support but do not prove the interpretation that the
coiled coil is not exposed, for example, because it is involved in
intermolecular dAg interactions essential for the structure of
the RNP.
There was a discordance between peptide ELISA values and
vRNP and dAg precipitation results obtained with some anti-
bodies. Thus, antibodies 15 and 17 (which were both raised
against determinants located in the carboxy third of dAg) were
nonreactive by ELISA but demonstrated high activity in vRNP
and dAg precipitation assays. On the other hand, polyclonal
antibody 11 (raised against a peptide representing residues 123
to 143) was moderately reactive by ELISA but nonreactive in
the immunoprecipitation assays. This suggests a possible dif-
ference in physical structure between the dAg utilized in the
ELISAs and that present in immunoprecipitation assays, with
resulting differences in the accessibility of the relevant
epitopes. This may reflect the fact that the liver-derived dAg
utilized in the ELISA was extracted from infected tissue under
denaturing conditions (6 M guanidine-HCl) followed by dial-
ysis against phosphate-buffered saline (24).
Our previous studies showed that treatment of vRNP with
VRC led to the release of RNA (21). We confirmed this and
found, in addition, that the constellation of exposed and un-
exposed dAg epitopes was not detectably changed by treatment
with VRC (Table 1). Apparently, the dAg multimer was un-
changed by the release of the RNA. However, this interpreta-
tion must be qualified in that separate studies have indicated
TABLE 1. Immune detection of epitopes on vRNP with specific antibodies
Antibody no.,









2 1 2 1
1, MAb 4A5 dAg-Sf None detected 5 3 3 4 ,100 1 1
2, rab 1066 aa 12–60 NDg 4 2 2 3 .400 1 2
3, rab 1067 aa 12–60 ND 2 1 2 3 .400 1 2
4, MAb 3.92 aa 12–60 ND 3 ND 2 ND ,100 2 ND
5, MAb 5.60 aa 12–60 ND 3 ND 3 ND ,100 2 ND
6, MAb 7.79 aa 12–60 ND 4 ND 3 ND ,100 2 ND
7, gp3 aa 58–78 aa 58–63, 67–73 67 3 95 90 6,250 1 1
8, gp4 aa 58–78 aa 66–72 65 ND 92 ND 6,250 1 ND
9, gp5 aa 82–102 aa 93–98 58 ND 53 ND 156,000 ND ND
10, MAb 3G3 dAg-S None detected 62 ND 36 ND 1,600 1 1
11, gp8 aa 123–143 None detected 9 3 5 5 6,250 2 ND
12, rab-LP2 aa 156–184 aa 156–160, 167–183 96 2 57 60 6,250 1 1
13, gp10 aa 156–184 aa 167–182 73 ND 66 ND 6,250 ND ND
14, gp12 aa 167–184 ND 56 ND 73 ND 6,250 ND ND
15, MAb 9E4 dAg-S None detected 61 3 66 71 ,100 1 1
16, MAb 1C4 dAg-S None detected 9 4 2 3 ,100 2 1
17, rab-LP3 aa 197–211 aa 200–210 71 2 47 41 ,50 1 1
Controls
18, MAb S14h HBsAg 14 16
19, MAb S14 HBsAg 3 4
20, MAb 10C6 HBcAg 4 4
21, rab a-dAg dAg-S 56 2 62 57
a The epitopes indicated were determined by PEPSCAN analysis (see Fig. 3), by using techniques previously described (25). In addition, antibody 1 was strongly
reactive in an ELISA with aa 12 to 60 Y. Also, antibodies 10, 15, and 16 were characterized by reactivities in a Western blot (immunoblot) analysis with fragments of
dAg. Antibody 10 reacted with aa 89 to 164, and antibodies 15 and 16 reacted with aa 164 to 195 (7).
b Each vRNP sample was tested both before (2) and after (1) treatment with vanadyl ribonucleosides (10 mM). We estimated that a value of ,5% represents the
background and a value of .10% is positive.
cMost of these values were as previously reported (23), except those for antibodies 1, 10, 15, and 16, which were subsequently derived by the same method (23), and
those for antibodies 2 to 6, which were assayed with an Abbott Delta-EIA diagnostic kit.
d The immunoblot data are results either from this study (antibodies 2, 3, 7, 8, and 11) or from reports by Wang et al. (23) and Hwang and Lai (7).
e The immunofluorescence data are results either from this study (antibodies 2, 3, 7, 12, and 17) or from a report by Hwang and Lai (7).
f dAg-S, small dAg.
g ND, not done.
h This control was done with intact HDV rather than isolated vRNP.
VOL. 70, 1996 EPITOPES EXPOSED ON HDV RNPs 5809
that the small and large forms of dAg can assemble into homo-
and heterodimers and higher-ordered multimers (12, 19, 24,
25). It is thus possible that individual dAg molecules within
dimers or multimers have different contact points with the viral
RNA and that an epitope recognized by an antibody can be in
contact with the RNA in one molecule but available for anti-
body binding and immunoprecipitation in its dimerization
partner. This may partially explain the inability to unmask
epitopes of dAg following release of RNA from vRNP com-
plexes by treatment with VRC.
We were able to extend our results obtained with the vRNP
isolated from virions to the nRNP isolated from the nuclei of
transfected cells (Table 1 and Fig. 2B). In terms of the epitopes
exposed to the antibodies used in this study and in terms of the
consequences of treatment with VRC, there was no significant
difference (unpublished observations). Apparently, the struc-
tural differences between vRNP and nRNP, as mentioned in
the introduction, do not extend to dAg epitope presentation.
Some comment must be made about the relationship be-
tween the epitopes found in this study to be exposed on the
RNP (Fig. 2 and Table 1) and previous reports of dAg domains
found to be immunodominant in the course of natural and
experimental HDV infections. Four such studies have been
reported (1, 18, 22, 24), and the predominant B-cell epitopes
were mapped to four regions, three of which correspond to the
nuclear localization signal, the putative assembly domain, and
the 19-aa C-terminal extension unique to the large dAg, all of
which were found to be exposed in our study. The fourth
domain, at the N terminus, aa 2 to 17, was also tested and
found to be negative, but corresponding antipeptide antibody
gp2 failed to recognize dAg in ELISA, immunoprecipitation,
immunoblotting, and immunofluorescence microscopy (23 and
unpublished observations). Therefore, this antibody was con-
sidered to be specific for the peptide but not for the dAg
protein and no conclusions could be drawn about the exposure
of the domain between aa 2 and 17.
In conclusion, the studies described here have provided a
better understanding of the structure of the two RNPs of
HDV. The immunological data obtained will be useful in fu-
ture studies of HDV genome replication and also in studies of
FIG. 2. Functional domains on dAgs and epitopes exposed on RNPs. (A)
Summary of the functional domains, as discussed in the text, that have been
mapped on the small and large forms of dAg (11, 13). dAg-L, large dAg. (B)
Specificities of the 17 antibodies, as described in Table 1, that were tested for the
ability to immunoprecipitate the HDV vRNP. The open boxes represent anti-
bodies that failed to bind vRNP. The shaded boxes represent antibodies that
were positive for binding. The partially shaded boxes represent not only anti-
bodies that were positive for binding but also those for which the relevant
epitopes were further defined by PEPSCAN analyses, as illustrated in Fig. 3.
N.L.S., nuclear localization signal.
FIG. 3. PEPSCAN analyses to define epitopes recognized by representative guinea pig antisera. Vertical bars indicate the absorbance obtained with each individual
pin (hexapeptide). The pins are labeled numerically according to the first amino acid residue of the synthetic hexapeptide. The horizontal bars indicate the locations
of the synthetic peptides used as immunogens for the antibodies being tested within the dAg domains scanned in the assays.
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the ability of RNPs to interact with the envelope proteins of
the helper virus to achieve assembly and release of progeny
virus particles.
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